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Abstract 
Degree project 
Programme in Medicine 
Title:  Analysis of overall survival and potential prognostic factors among lung cancer 
patients treated with curative radiotherapy between 2002-2016 in Region Västra 
Götaland 
Author: David Eriksson 
Year:  2018 
Institution: Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden 
 
Background: Radiotherapy is an important treatment modality for lung cancer patients of all 
stages: from high dose curative intended treatment in stage I-III to palliative treatment in 
stage IV disease. More than 100 patients are treated with potentially curative radiotherapy 
each year in Region Västra Götaland (VGR), but outcome measures on a population-basis 
remains to be evaluated.  
Aim: To evaluate overall survival for lung cancer patients treated with radiotherapy with 
curative intent in VGR during 2002-2016 and to compare survival depending on time interval, 
radiation dose, as well as other potential prognostic factors.  
Methods: Patient and tumor information were retrospectively collected from quality registers, 
medical records and radiotherapy databases. Patients were analyzed in three groups: 
stereotactic body radiation therapy (SBRT) for stage I non-small cell lung carcinoma 
(NSCLC), chemoradiotherapy for locally advanced NSCLC and chemoradiotherapy for small 
cell lung carcinoma (SCLC). Multivariate survival analyses were performed using the Cox 
proportional hazards model. 
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Results: 1421 patients were included in the study. Three-year overall survival was 47-55 %, 
24-35 % and 20-28 % for the SBRT, locally advanced NSCLC and SCLC groups 
respectively. There was no significant difference in survival rates between time intervals in 
any group but trends for improved survival among locally advanced NSCLC patients and 
declining survival among SCLC patients were observed. Male sex, a poor performance status 
and NSCLC tumors located in the lower lobe were associated with an inferior survival. 
Conclusion: The real-life data from this study indicates that overall survival for NSCLC 
patients in VGR are comparable to previously reported results in clinical trials. A trend for 
improved survival over time was seen among locally advanced NSCLC patients, albeit not 
statistically significant. Overall survival for SCLC patients was lower than expected and may 
also have declined over time. 
 
Key words: Lung cancer, curative chemoradiotherapy, overall survival 
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Introduction/Background 
Epidemiology 
In the beginning of the 20th century lung cancer was an uncommon disease, viewed as ”a 
medical curiosity too rare to be of much practical importance” (1, 2). This was to radically 
change by the midth-20th-century following the dawn of the global smoking epidemic (3). 
Today, lung cancer constitutes a huge burden on society around the globe. With an estimated 
1.6 million deaths due to lung cancer in 2012 and approximately 1.8 million new cases the 
same year, lung cancer is the leading cause of cancer death in the world as well as one of the 
most frequently diagnosed cancers (4). In Sweden about 3650 people are diagnosed with lung 
cancer each year, and consistent with the rest of the world the prognosis for diagnosed 
patients is poor here as well, with a relative 5-year survival rate of approximately 13.6% for 
men and 19.4% for women (5).  
 
Risk factors and prevention 
Cigarette smoking is undisputedly the largest risk factor for developing lung cancer, 
accounting for the vast majority of all lung cancer cases. An excess relative risk of at least 20 
has been observed in current smokers compared with lifetime nonsmokers in several studies 
(6). The number of cigarettes smoked and duration of smoking is determinant to the excess 
risk but no risk-free level of smoking has been observed (6). Passive smoking, or inhalation of 
so called environmental tobacco smoke, in nonsmokers is also considered a carcinogen, 
although not nearly as strong as active smoking is for developing lung cancer (7). Other well-
established risk factors are exposure to asbestos, radon, arsenic and previous inflammatory 
lung diseases such as chronic bronchitis or chronic obstructive pulmonary disease (8). Indoor 
air pollution, in particular coal smoke, is an important risk factor in developing countries, 
where nonsmokers constitutes a much larger proportion of lung cancer patients (9). Growing 
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evidence suggests that lung cancer in never-smokers is in part a different disease than lung 
cancer attributable to cigarette smoking, and that further research is needed to determine the 
optimal treatment strategies for these separate groups of lung cancer (7). Dietary and 
nutritional factors are also thought to play a role in prevention of lung cancer since several 
retrospective investigations have shown protective effects of high intake of fruit and 
vegetables, although no single dietary nutrient has been successfully isolated (8). 
 
Histology 
Traditionally, lung cancer has been divided into two groups based on their histopathological 
and clinical presentation: small cell lung cancer (SCLC) and non-small cell lung cancer 
(NSCLC), where NSCLC constitutes the vast majority, 80-85%, of lung cancer cases (10). 
However, this traditional classification has developed, and in the recent publication of the 
2015 World Health Organization Classification of Lung tumors, the major histologic types of 
carcinomas are: squamous cell carcinoma, adenocarcinoma, and (now belonging to the 
neuroendocrine tumors) SCLC and large-cell carcinoma (11, 12). One important reason for 
this revision of lung tumor classification is the development of specific therapies targeting 
oncoproteins found in various NSCLC tumors, mainly adenocarcinomas but also in squamous 
cell carcinomas (12). Subsequently, adenocarcinomas and squamous cell carcinomas are 
further classified into several subgroups, but the use of a more specific classification than 
simply adenocarcinoma, squamous cell carcinoma or NSCLC NOS (not otherwise specified) 
is not common in clinical practice today (13).  
 
Presenting signs and symptoms 
More than 9/10 of patients with lung cancer are symptomatic when first diagnosed, but most 
of the symptoms will not emerge before the tumor has reached an advanced stage (14). 
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Presenting signs and symptoms can therefore be predictive of the prognosis of the cancer: 
Patients who are asymptomatic at diagnosis have significantly improved survival rates 
compared to symptomatic patients (15).  
     The most common symptoms related to the primary lung tumor is cough with or without 
sputum, dyspnea, hemoptysis and diffuse chest discomfort. Intrathoracic extension of the 
primary lung tumor or lymphatic spread that affects nerves and large blood vessels within the 
thoracic region could cause mass effects like Horner syndrome; hoarseness or dysphagia 
caused by recurrent laryngeal nerve palsy; phrenic nerve paralysis; and vena cava superior 
syndrome. Intrathoracic metastases to the pericardium and myocardium of the heart also 
occurs, usually presenting with arrhythmias or cardiac tamponade (14, 16). Chest pain that is 
more severe and localized could be an indication of primary tumor invasion of the pleura or 
chest wall, or worse, a sign of rib metastasis. The metastatic pattern of lung cancer varies 
depending on histological type, sex and age of the patient, but the most common metastatic 
sites overall are the liver, bones, central nervous system, respiratory system, adrenal gland 
and lymph nodes (14, 17). Typical signs of metastasized lung cancer include bone pain; 
weakness and weight loss caused by hepatic metastases; seizures, confusion, personality 
changes, focal neurologic signs, etc. produced by brain metastases; and palpable 
lymphadenopathy in the supraclavicular fossa (14, 16). 
 
Diagnosis and staging 
In order to give the patient the best possible treatment, a comprehensive diagnostic 
investigation is needed to accurately determine the tumor type and the lung cancer stage. The 
best initial diagnostic tool for assessment of extra-thoracic disease remains a thorough 
anamnesis and physical examination of the patient (2). Based on clues from the clinical 
evaluation, the investigational procedure continues with the most appropriate diagnostic tests. 
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Commonly required investigations for lung cancer, apart from medical history and physical 
examination, include imaging techniques such as chest X-ray, CT of the thorax, PET/CT (see 
below) and brain MRI; blood test analyses, e.g. liver, renal and bone status; tissue samples 
essentially obtained with bronchoscopy, transthoracic techniques or biopsies from metastasis 
sites. Additionally, endobronchial ultrasound and/or esophageal ultrasound for fine needle 
aspiration and evaluation of regional lymph nodes is used in selected cases (18). The biopsies 
are in addition to histopathological assessment also utilized to perform a variety of molecular 
pathology analyses in order to identify tumors sensitive to biological therapies such as EGFR 
tyrosine kinase inhibitors or other kind of targeted therapies. (11, 16).  
     The current basis for staging of lung carcinomas is the tumor-nodes-metastases (TNM) 
system as revised and described in the 8th edition of the TNM Classification of Malignant 
Tumors, effective since January 2017 (18, 19). In this classification system, T refers to size 
and growth of the primary tumor; N to the presence of nodal metastases; and M refers to 
presence of distant metastases. The TNM classification correlates to a certain cancer stage 
between I and IV. For instance, stage I includes small tumors confined to the lung (T1-T2), 
whereas presence of distant metastases (M1a-M1b) always translates into stage IV regardless 
of Tumor or Nodal classification (19).  
     Simultaneously with the tumor-directed investigations, a complete analysis of patient 
factors such as lung function, physical function, estimated postoperative quality of life, 
comorbidities (e.g. chronic obstructive lung disease or cardiovascular diseases) and 
performance status is performed and is decisive for choosing the best treatment strategy for 
the patient in each individual case (20, 21).  
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PET/CT     
PET/CT scans has seized an important role in the management of lung cancer patients. PET is 
a nuclear medicine technique used to detect tissues with increased metabolic activity, like 
cancer cells or inflammation, by tracing uptake of positron-emitting fluorodeoxyglucose. By 
combining PET with a CT scan, three-dimensional images with both anatomical and 
metabolic information is accomplished. PET-CT is primarily used as a standard imaging 
technique for staging of patients considered for radical treatment, and its negative predictive 
values are excellent at 85-95 % (16, 22, 23). However, there are some well-known limitations 
of this technique, for example inability to detect cancers with low metabolic activity or to 
distinguish cancer from inflammation. In addition to initial staging, PET/CT is used to 
improve planning of radical radiotherapy for lung cancer (24). In VGR, PET/CT was 
introduced as a standard diagnostic/staging technique for lung cancer in 2010, but its impact 
on treatment outcomes has not yet been evaluated. 
 
Treatment 
One important reason for the poor prognosis of lung cancer is the fact that the disease has 
often already spread to other organs when diagnosed. More than 50% of patients have a 
metastasized disease when diagnosed and cannot be treated curatively (13). Potentially 
curative treatment options is possible in most cases for the remaining patients but the 
therapeutic strategy depends on stage and histology of the cancer as well as the comorbidity 
and, not least, the wish of the patient (13). 
 
Surgery 
Surgical radical resection of the tumor is the foremost curative treatment for patients with 
lung cancer. It is the first-line therapy for NSCLC of stage I-II and in selected cases of stage 
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III, and a viable alternative to chemoradiotherapy in some cases of stage I SCLC (16, 25). 
Lobectomy is the surgical procedure of choice for tumors confined to one lobe, whereas 
pulmectomy is performed when the cancer involves all lobes in one lung or the main 
bronchus (16). Limited resections as a method of parenchyma-saving surgery could be 
preferable in some specific instances, but does generally not replace complete resection (18). 
Moreover, resected patients should in most cases (except stage IA) be treated with 
postoperative adjuvant chemotherapy, as it reduces the risk for recurrence and improves 
survival. In case of non-radical dissection, chemoradiotherapy for locally advanced NCSLC 
as described below should be considered postoperatively (16).  
     Surgery as a treatment strategy for lung cancer should always be curative in its intent and 
not offered as a palliative measure. In total, only 20-25 % of patients with NSCLC are eligible 
for surgery (26), and many of them will suffer a postoperative recurrence with deadly 
outcome (27). In spite of being the primary curative treatment, the total five-year survival rate 
after surgical resection of lung cancer is just over 50 % in Sweden (16). 
 
Radiotherapy 
While surgery is the main curative treatment for early stage NSCLC, radiotherapy is an 
essential curative modality too, and in addition used broadly as palliative treatment. It is used 
in the curative setting in many cases of NSCLC, e.g. for locally advanced cancer or smaller 
tumors in patients that are medically inoperable, and chemoradiotherapy is virtually the only 
effective option when it comes to treatment of SCLC (16). Radiotherapy is however not 
without risk. Common side-effects related to normal tissue irradiation include pneumonitis, 
lung fibrosis, and acute esophagitis (16). Different fractionation strategies and total doses are 
used depending on tumor and patient factors in order to optimize treatment effect while 
reducing the risk for normal tissue reactions. The standard radiotherapy fractionation 
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technique in clinical practice is so called conventional fractionation, where the dose is 
delivered with one fraction of 1.8-2.0 Gy daily for five days a week during several weeks 
until the total dose is reached. Hyperfractionation and hypofractionation are other commonly 
used techniques. Hypofractionation means that the total dose is divided into fewer and larger 
fractions, with the overall treatment period considerably shorter than in conventional 
(standard) radiotherapy. Conversely, hyperfractionated radiotherapy means that the total dose 
is split into a large number of smaller fractions than in conventional radiotherapy, and usually 
delivered with more than one fraction per day. In this way, hyperfractionation allows for the 
possibility to achieve a higher total dose during a conventional overall treatment period. 
Finally, radiotherapy can be delivered with accelerated fractionation, where the overall 
treatment period is considerably shortened but the numbers and doses of fractions are 
typically conventional. Accelerated fractionation may also be combined with hypo- or 
hyperfractionated regimens (28).  
 
Radiotherapy in early-stage NSCLC 
Despite an early-stage cancer, many patients are medically inoperable when diagnosed with 
NSCLC due to poor lung function or other comorbidities. These inoperable patients were 
earlier treated with conventionally fractioned radiotherapy doses of 1.8-2.0 Gy/day for a total 
radiation dose of around 60 Gy. However, as concluded by Qiao et al. in their review from 
2003, the outcome of conventionally fractionated radiotherapy as treatment of stage I NSCLC 
was disappointing with a mean 3-year overall survival of 34 % and local tumor control rate of 
50 % (29). These results were of course significantly lower than what could be achieved with 
surgery on operable stage I NSCLC patients, and mainly attributed to too low total radiation 
doses (16). During the last decade, a different radiation technique has been developed: 
stereotactic body radiotherapy (SBRT). This is a high precision technique of hypofractionated 
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radiotherapy that allows for deliverance of very large radiation therapy doses against the 
tumor in just a few fractions, whilst sparing surrounding normal tissues to a great extent. Due 
to a substantial amount of literature describing excellent results in quality of life and survival, 
SBRT has become a new standard therapy for inoperable patients with stage I NSCLC. 
Furthermore, a recent comparison to conventionally fractionated radiotherapy showed less 
toxicity and improved quality of life with SBRT (16, 30, 31). Different doses and 
fractionation for SBRT has been used both internationally and in Sweden, but the most 
common setup in Sweden and in VGR is currently 45 Gy given in 3 fractions of 15 Gy during 
one week (16). This fractionation has been extensively studied in clinical trials in the last 
decade, and its usefulness in treating peripherally located early stage NSCLC is well-
established (32, 33). However, some studies have reported an unacceptably high risk for 
major toxicities when such intensified fractionations are used to treat central tumors located 
too close to the bronchial tree or other critical mediastinal structures (34, 35). Haasbeek et al. 
found that both satisfactory treatment results and no excess risk in toxicity could be achieved 
by using a less intensified, risk-adapted SBRT delivered in 8 fractions of 7 Gy against 
centrally located lung tumors (36). In VGR today, similar risk-adapted and less intensified 
SBRT schedules that results in biologically lower doses (currently 56 Gy in 8 fractions) are 
commonly used to treat early stage NSCLC tumors in high-risk locations. However, clinical 
outcomes for the different types of SBRT in VGR remains to be evaluated, and there is 
currently a lack of studies comparing outcomes for different SBRT doses. 
 
Radiotherapy in locally advanced NSCLC 
Patients with stage III NSCLC, i.e. locally advanced disease, are a heterogeneous group 
comprising almost 3/10 of newly diagnosed lung cancer cases. Most of these patients are not 
eligible for surgery, but approximately 50% can be offered curative radiotherapy with 
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concurrent platinum-based chemotherapy (16). The degree of nodal invasion is determinant of 
the prognosis (37), which remains poor even with curative treatment: the 2-year survival rate 
has been reported to be only 20% (16). Since NSCLC stage III is such a diverse group of 
patients, it is all the more important to conduct a comprehensive diagnostic investigation, 
which should include contrast enhanced CT scans, brain MRI and PET/CT, and sometimes 
mediastinal invasive staging. Treatment strategy decisions should always be rooted in 
multidisciplinary team meetings (18). 
     There are strong indications of a dose-response relationship for irradiation of locally 
advanced NSCLC, although somewhat conflicting findings on the subject have been observed 
(38-40). Based on up-to-date research, the previous standard radiation dose of 60 Gy is now 
regarded as inadequate and total doses exceeding 70 Gy are deemed experimental and not 
recommended in clinical practice. While the optimal total dose remains uncertain, the 
effectiveness of concomitant chemotherapy and radiotherapy with total doses exceeding 60 
Gy is well-supported. Hence, currently recommended total doses in Sweden are 66-70 Gy, 
dose levels that are considered well-documented despite a lack of randomized clinical trials 
(16). The typical fractionation schedule in clinical use is conventional fractionation (2 Gy per 
day up to 10 Gy per week), though several studies have shown promising results from 
accelerated radiotherapy regimens compared to conventional fractionation (41). However, 
additional randomized clinical trials are required before unconventional fractionation can be 
safely implemented into clinical guidelines (16). In VGR, patients with stage III NSCLC are 
treated according to current recommendations with a slight acceleration (70 Gy in 6 fractions 
per week plus 3 cycles of chemotherapy), but as with SBRT, clinical outcomes of this 
treatment, and its predecessors, are yet to be evaluated. 
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Radiotherapy in SCLC 
In contrast to NSCLC, the standard treatment for most cases of SCLC is not surgery, but 
chemoradiotherapy. This is due to the fact that SCLC is a very fast-spreading cancer that has 
usually already advanced to an unresectable stage by the time of diagnosis. It is, however, 
very chemo- and radiosensitive. (42). Hence, platinum-based chemotherapy constitutes the 
foundation of the treatment strategy of SCLC, while combination with radiotherapy 
significantly improves the prognosis.  
     As the risk for brain metastasis is considerable in SCLC patients, with a cumulative 
incidence of 50 % at two years after diagnosis (43), patients with SCLC in complete or almost 
complete remission after first-line therapy should be offered prophylactic cranial irradiation, 
as it significantly reduces the risk for brain metastases and improves survival rates (16).  
     Thoracic irradiation in addition to chemotherapy has been shown to improve long term 
survival rates (44). Hyperfractionation is superior to conventional fractionation because of the 
rapid proliferation of SCLC tumors, a theory which was supported in a randomized study by 
Turrisi et al. in 1999 (45), and a dose-response relationship has also been determined for 
radiation therapy in SCLC (46). However, there is currently a lack of consensus regarding 
optimal total doses in SCLC, as very few randomized clinical trials comparing different doses 
of radiotherapy has been published so far. The best clinical outcomes has been observed for 
doses ranging from 45 to 60 Gy delivered in a hyperfractionated schedule, and the 
recommendation in Sweden is concurrent chemotherapy and hyperfractionated radiotherapy 
with 1.5 Gy two times daily to a total dose of 45-60 Gy (16). Clinical practice for treatment of 
SCLC patients in VGR is in line with this recommendation, but the clinical outcomes still 
need to be evaluated. 
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Specific objectives 
The aim of this degree project is 
v To evaluate overall survival for patients with stage I NSCLC treated with SBRT 
during 2002-2016 and to compare overall survival rates depending on time interval, 
radiation dose, staging with PET/CT as well as other potential prognostic factors.  
v To evaluate overall survival rates for patients with stage III NSCLC treated with 
chemoradiotherapy during 2002-2016 and to compare overall survival rates depending 
on time interval, radiation dose, staging with PET/CT as well as other potential 
prognostic factors.  
v To evaluate overall survival rates in patients with stage I-III SCLC treated with 
concurrent chemoradiotherapy with hyperfractionated accelerated radiotherapy during 
2002-2016 and to compare overall survival rates depending on time interval, radiation 
dose, staging with PET/CT as well as other potential prognostic factors.   
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Methods and material 
Study design	 
We conducted a quantitative retrospective population-based study of all the patients in Region 
Västra Götaland with NSCLC or SCLC that received radiotherapy with curative intent during 
2002-2016. The aim was to study overall survival depending on time period, ECOG 
performance status, smoking habits, age at the start of treatment, gender, TNM classification 
and stage, radiation dose and technical aspects as use of PET/CT. Since much has happened 
between 2002 and 2016 in the field of curative radiotherapy for lung cancer, we wanted to 
divide the patient population into different time intervals of appropriate and equal lengths, in 
order to appreciate how the continuous development has affected survival. The time period 
between 2002-2016 was therefore divided into three time intervals: 2002-2006, 2007-2011 
and 2012-2016. A cutoff in follow-up time after the radiotherapy was set to three years, in 
order to control for survival bias favoring more recent treatment regimens.  
 
Study population and data collection 
The inclusion criteria were patients with pathologically or, in event of missing pathological 
diagnosis, clinically and radiologically diagnosed lung cancer, who had received radiotherapy 
with curative intent between 2002 and 2016, either at Sahlgrenska University Hospital in 
Gothenburg (SU) or Södra Älvsborgs Hospital in Borås (SÄS). The patients were primarily 
identified through databases at the radiation therapy units at SU and SÄS, where all cancer 
patients treated in VGR were listed. Lung cancer patients were extracted from the databases 
by searching for patients with lung cancer as their primary diagnosis code. The total radiation 
dose and type of radiation treatment for each one of the patients were determined from the 
radiotherapy data and, when necessary, medical records. Patients from this primary material 
were in the next step excluded due to any of the following exclusion criteria: lung tumors 
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other than SCLC or NSCLC; postoperative radiotherapy; palliative treatment; concurrent 
radiotherapy for malignancies other than lung cancer; bilateral tumors i.e. stage IV disease; 
interrupted treatment/suboptimal total radiation dose; missing social security number. If a 
patient had suffered a relapse or a second primary lung cancer and therefore received more 
than one radiotherapy course during the time period, only the first course was included. 
     All included patients were then classified into three different main groups: SBRT for stage 
I NSCLC, curative chemoradiotherapy for locally advanced NSCLC and curative 
chemoradiotherapy for SCLC. 
     Thereafter, the patient data was matched against the national Swedish Lung Cancer 
Registry for extraction of patient and tumor variables i.e. ECOG performance status, smoking 
habits, use of PET/CT, date of death, TNM classification and stage, histology and anatomical 
location. Patients that were not found in the lung cancer registry were rescreened using 
medical records and could be excluded due to previously mentioned reasons. If they still 
fulfilled the inclusion criteria, missing data were extracted from the medical records and 
added to the database.  
 
Statistical analysis 
The statistical analyses were made in R version 3.4.3. The Kaplan-Meier method was used to 
calculate survival rates. The Log-Rank test was used to compare the survival rate for each 
variable. A multivariate survival analysis was performed using the Cox proportional hazards 
model. The final model was adjusted for treatment period, age, gender, performance status, 
smoking habits, stage of cancer, histology, location of tumor, use of PET/CT and total 
radiation dose. The Wald test was used to test the significance of individual regression 
coefficients. A result was considered significant when the P value was <0.05. 
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     Age was analyzed as a continuous variable and not by age-group. Supplementary analyses 
were performed for five-year survival and PET/CT. Five-year OS was only estimated for the 
two earlier treatment intervals (2002-2006 and 2007-2011) and staging with PET/CT was 
only analyzed for the two latter (2007-2011 and 2012-2016), since it was implemented in 
clinical practice as late as 2010. 
 
Ethics 
After the collection of data, all patient data were anonymized by giving every patient an 
individual code. The coding key was stored separately from patient data. Moreover, the study 
is a retrospective analysis of patient records. Thus, it has not affected treatment or 
management of participating patients in any way. Permission from The Regional Ethical 
Review Board in Gothenburg to conduct this retrospective patient record study has been 
granted.   
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Results 
The extracted files from the radiation therapy system of lung cancer patients treated in VGR 
between 2002 and 2016 included 2232 patients. 2044 of these patients were treated at 
Sahlgrenska University Hospital and 188 patients at Södra Älvsborgs Hospital. The primary 
files of radiation therapy, medical records and quality registers were used for sorting and 
exclusion, and in the end 1421 lung cancer patients that met the inclusion criteria remained. 
Data for 173 patients were missing in the quality register and these patients were rescreened 
using medical records. 159 of the rescreened patients were included in the study. Details on 
exclusions are showed in Figure 1.  
     Gender distribution in the entire population was even with 51 % female patients and 49 % 
male. The ECOG performance status (PS) score in the majority of patients were 1, but a 
relatively large proportion (16 %) were classified as PS=2. Only a very small proportion had 
PS=3-4 (see Table 1a-b, 2a-b, 3a-b). 
     346 of the lung cancer patients were treated with SBRT for stage I NSCLC disease, 806 
patients received chemoradiotherapy for locally advanced NSCLC, 269 patients received 
hyperfractionated accelerated chemoradiotherapy for SCLC. Details on the study population 
for each group are shown in Table 1a-1b, 2a-2b and 3a-3b.  
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Figure	1,	Flow	chart	detailing	the	exclusion	and	inclusion	of	patients	in	the	study 
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SBRT for stage I NSCLC 
The use of SBRT clearly increased between the time intervals: 53 patients received SBRT in 
the first interval (2002-2006), 115 in 2007-2011 and finally 178 patients between 2012 and 
2016 (Table 1a). Three-year survival for the SBRT treatment groups was 55 % in the 2002-
2006 period, 47 % between 2007-2011 and 54 % in the 2012-2016 period (Fig. 1.1). Five-
year survival was analyzed for the first two treatment periods and was 30 % for both 2002-
2006 and 2007-2011 (see Fig. 1.2 in Appendix A). Median survival was 33.2 months for the 
2007-2011 time interval and 38.5 months for 2002-2006. No median value was available for 
2012-2016. There was no significant difference in survival between treatment intervals (Table 
1c). The results of the Cox proportional hazard model are showed in Table 1c. When 
analyzing potential factors for survival a gender difference could be observed in the 
multivariate analysis where males had an inferior survival compared to women with a hazard 
ratio (HR) of 1.6 for both three- and five-year OS (95 % confidence interval 1.2 – 2.2, 
p=0.002 and 1.1 – 2.5, p=0.016 respectively). There was also a lower survival among patients 
with higher ECOG PS scores: for example, patients with PS=2 had a doubled mortality rate in 
three year-survival compared to PS=0 (HR=2.1, 95 % CI 1.2 – 3.8, p<0.05).  
     Tumors located in the inferior lobe were associated to an adverse effect on three-year 
survival compared to the middle and superior lobe (HR=1.44, 95 % CI 1.04 – 1.98, p=0.03). 
Five-year survival was also inferior but not statistically significant (HR=1.49, 95 % CI 1.0 – 
2.23, p=0.052). 
     Use of PET/CT significantly improved survival in univariate analysis but this significance 
was not maintained in the multivariate model. No significant differences could be observed in 
the multivariate analysis with regard to time interval, age at the start of treatment, smoking 
habits, T-stage, tumor laterality or total radiation doses, albeit trends were noted with regard 
to T1 vs T2 tumors (Fig. 1.2) and 45 vs 56 Gy (see Fig. 1.7 in Appendix A). Histological 
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diagnosis and tumor laterality were analyzed but did not have an impact on survival and was 
therefore not included in the model. The following factors were seen as important factors and 
included in the model: treatment period, gender, smoking habits, ECOG PS, lobar location of 
the tumor, T-stage, age and total radiation dose. The Kaplan-Meier graphs for these factors in 
univariate analyses are shown in Figure 1.1-1.8 (Fig. 1.6-1.8 are shown in Appendix A). 
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Table	1a:	Demographics	of	patients	treated	with	SBRT 
	 2002-2006	 2007-2011	 2012-2016	 Total	
Median	age	(range)	 78	(58-91)	 76	(52-94)	 77	(56-91)	 -	
	 No.	of	patients	(%)	
Patients	treated	with	
SBRT	
53	(100)	 115	(100)	 178	(100)	 346	(100)	
Gender	 	
Female	 27	(50.9)	 59	(51.3)	 108	(60.7)	 216	(56.1)	
Male	 26	(49.1)	 56	(48.7)	 70	(39.3)	 173	(43.9)	
Smoking	status	 	
Smokers	 19	(35.8)	 43	(37.4)	 72	(40.4)	 134	(38.7)	
Ex-smokers	 30	(56.6)	 59	(51.3)	 91	(51.1)	 180	(52.0)	
Non-smokers	 3	(5.7)	 12	(10.4)	 15	(8.4)	 30	(8.7)	
Missing	 1	(1.9)	 1	(0.9)	 0	(0.0)	 2	(0.6)	
	Diagnostic	PET-CT	 	
No	 49	(92.5)	 27	(23.5)	 9	(5.1)	 85	(24.6)	
Yes	 4	(7.5)	 88	(76.5)	 169	(94.9)	 261	(75.4)	
ECOG	PS*	 	
0	 7	(13.2)	 19	(16.5)	 20	(11.2)	 46	(13.3)	
1	 33	(62.3)	 61	(53.0)	 96	(53.9)	 190	(54.9)	
2	 12	(22.6)	 32	(27.8)	 54	(30.3)	 98	(28.3)	
3-4	 1	(1.9)	 3	(2.6)	 7	(3.9)	 11	(3.2)	
Missing	 0	(0.0)	 0	(0.0)	 1	(0.6)	 1	(0.3)	
Total	radiation	dose	 	 	 	 	
40	Gy	 1	(1.9)	 14	(12.2)	 11	(6.2)	 26	(7.5)	
45	Gy	 52	(98.1)	 100	(87.0)	 154	(86.5)	 306	(88.4)	
56	Gy	 0	(0.0)	 0	(0.0)	 12	(6.7)	 12	(3.5)	
Missing	 0	(0.0)	 1	(0.9)	 1	(0.6)	 2	(0.6)	
*=Eastern	Cooperative	Oncology	Group	Performance	status 
Table	1b:	Tumor	information	of	patients	treated	with	SBRT	
	 2002-2006	 2007-2011	 2012-2016	 Total	
	 No.	of	patients	(%)	
Histological	diagnosis	
	
Squamos	cell	
carcinoma	
13	(24.5)	 18	(15.7)	 23	(12.9)	 54	(15.6)	
Adenocarcinoma	 19	(35.8)	 27	(23.5)	 57	(32.0)	 107	(29.8)	
NSCLC	NOS**	 21	(39.6)	 70	(60.9)	 89	(55.1)	 189	(56.6)	
Tumor	location,		
side	
	
Right	 35	(66.0)	 65	(56.5)	 104	(58.4)	 204	(59.0)	
Left	 18	(34.0)	 50	(43.5)	 74	(41.6)	 142	(41.0)	
Tumor	location,	lobe	
	
Upper	lobe	 30	(56.6)	 66	(57.4)	 105	(59.0)	 201	(58.1)	
Middle	lobe	 3	(5.7)	 7	(6.1)	 7	(3.9)	 17	(4.9)	
Lower	lobe	 20	(37.7)	 41	(35.7)	 66	(37.1)	 127	(36.7)	
Missing	 0	(0.0)	 1	(0.9)	 0	(0.0)	 1	(0.3)	
T	(primary	tumor)	 	
T1	 31	(58.5)	 76	(66.1)	 125	(70.2)	 232	(67.1)	
T2	 22	(41.5)	 39	(33.9)	 53	(29.8)	 114	(32.9)	
*=NSCLC	Not	otherwise	specified	
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Table	1c:	p-values	and	Hazard	ratios	for	variables	in	the	SBRT	group	
Variable	 p-value	in	
univariate	
analysis	
HR	(95%	CI)	 p-value	in	multivariate	
analysis	
	
Treatment	interval	
2002-2006	
2007-2011	
2012-2016	
0.436		 	
Reference	
1.22	(0.75	-	1.98)	
0.97	(0.6	-	1.57)	
	
	
0.426	
0.912	
Gender	
Female	
Male	
0.001	
	
	
Reference	
1.60	(1.15	–	2.22)	
	
	
0.005	
Smoking	habits	
Smoker	
Ex-smoker	
Never-smoker	
0.378	
	
	
Reference	
0.75	(0.53	–	1.04)	
0.54	(0.28	–	1.04)	
	
	
0.087	
0.067	
Tumor	location,	lobe	
Upper	lobe	
Middle	lobe	
Lower	lobe	
0.047	 	
Reference	
0.72	(0.29	–	1.79)	
1.44	(1.04	–	1.98)	
	
	
0.478	
0.029	
ECOG	Performance	status	
0	
1	
2	
3-4	
0.002	
	
	
Reference	
1.60	(0.90	–	2.83)	
2.12	(1.17	–	3.84)	
4.67	(1.98	–	11.00)	
	
	
0.108	
0.013	
<0.001	
T-stage	
T1	
T2	
0.035	
	
	
Reference	
1.27	(0.91	–	1.78)	
	
	
0.154	
Age	at	start	of	treatment	
Continuous	variable	
0.115	 	
1.02	1.00	–	1.05)	
	
0.059	
Total	radiation	dose	
40	Gy	
45	Gy	
56	Gy	
0.309	
	
	
	
Reference	
0.75	(0.43	–	1.28)	
0.75	(0.36	–	2.56)	
	
	
0.287	
0.933	
 
	
	
Figure	1.1,	Overall	survival	among	lung	cancer	patients	treated	with	stereotactic	body	radiotherapy	depending	on	during	in	
which	time	interval	patients	received	their	treatment.			
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Figure	1.2,	Overall	survival	among	lung	cancer	patients	treated	with	stereotactic	body	radiation	therapy	depending	on	the	
stage	of	the	tumor	
	
Figure	1.3,	Overall	survival	among	lung	cancer	patients	treated	with	stereotactic	body	radiation	therapy	depending	on	the	
gender	of	the	patients 
	
	
Figure	1.4,	Overall	survival	among	lung	cancer	patients	treated	with	stereotactic	body	radiotherapy	depending	on	the	ECOG	
performance	status	score	of	patients	
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Figure	1.5,	Overall	survival		depending	on	the	lobar	location	of	the	tumor	among	lung	cancer	patients	treated	with	
stereotactic	body	radiation	therapy		
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Curative chemoradiotherapy for locally advanced NSCLC 
Details on the locally advanced NSCLC population are shown in Table 2a-2c. Three-year 
survival in the locally advanced NSCLC chemoradiotherapy group was 24 %, 27 % and 35 % 
for 2002-2006, 2007-2011 and 2012-2016, respectively (Fig. 2.1). Five-year survival was 
estimated to 15 % for 2002-2006 and 18 % for 2007-2011 (Fig. 2.5 in appendix). There was a 
significant difference in three-year survival between the time periods (p=0.037) in the 
univariate analysis, but this difference was not maintained in multivariate analyses. No 
significant difference was found when five-year survivals was compared. Median survival 
was 15.3, 18.2 and 18.4 months for each time interval.  
     The results of the Cox proportional hazard model are showed in Table 2c. Total radiation 
dose was divided into four groups: 54-63 Gy (n=141), 64-66 Gy (n=298), 68-70 Gy (n=354) 
and >70 Gy (n=5). 8 patients had a missing total dose. The patients with >70 Gy were 
included in a trial and already known to have an inferior survival. 
     Patient survival was negatively affected by more advanced stages of cancer. However, the 
results in three- and five-year survival analyses were significant only when stage IIIB or IV 
was compared to IA-IIB, not IIIA. 52 patients were categorized as stage IV lung cancer and 
they suffered the greatest risk (HR=2.0, 95 % CI 1.36 – 2.97, p<0.001). The 325 patients with 
stage IIIB showed a 50 % higher risk compared to stage IA-IIB (HR=1.5, 95 % CI 1.14 – 
1.87, p=0.003).  
     25 % of patients (n=198) with locally advanced NSCLC had ECOG PS=0, and 64 % 
(n=516) had ECOG PS 1. 10.7 % (n=86) had PS=2 and only 0.6 % (n=5) had PS=3-4. Our 
analysis showed that higher ECOG PS score were associated with lower three-year survival: 
HR=1.4 for PS=1 (p=0.007), 2.0 for PS=2 (p<0.001) and a borderline significant HR=3.0 for 
PS=3-4 (p=0.06). The same trend was seen in the five-year survival analysis. There was no 
significant difference with regard to age at start of treatment, smoking habits, tumor laterality, 
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histological diagnosis and TNM-stage. Borderline significant results were observed with 
regard to in which lung lobe the tumors were located. Tumors located in the lower lobe had an 
adverse effect on survival in the three-year survival (HR=1.44, 95 % CI 1.00 – 2.08, p=0.050) 
and in the supplementary PET/CT analysis, tumors located in the middle lobe were associated 
with a better chance for survival (HR=0.43, 95 % CI 0.19 – 0.99, p=0.048). 
 
Table	2a:	Demographics	of	the	locally	advanced	NSCLC	group	
	 2002-2006	 2007-2011	 2012-2016	 Total	
Median	age	(range)	
66	(41-84)	 68	(15-86)	 69	(38-87)	 -	
	
No.	of	patients	(%)	
Patients	treated	with	
radiotherapy	for	
NSCLC	
233	(100)	 293	(100)	 280	(100)	 806	(100)	
Gender	 	
Female	 103	(44.2)	 139	(47.4)	 139	(49.6)	 381	(47.3)	
Male	 130	(55.8)	 154	(52.6)	 141	(50.4)	 425	(52.7)	
Smoking	status	 	
Smokers	 139	(59.7)	 131	(44.7)	 136	(48.6)	 406	(50.4)	
Ex-smokers	 74	(31.8)	 133	(45.4)	 121	(43.2)	 328	(40.7)	
Non-smokers	 19	(8.2)	 28	(9.6)	 22	(7.9)	 69	(8.6)	
Missing	 1	(0.4)	 1	(0.3)	 1	(0.4)	 3	(0.4)	
	Diagnostic	PET-CT	 	
No	 232	(99.6)	 193	(65.9)	 16	(5.7)	 441	(54.7)	
Yes	 1	(0.4)	 100	(34.1)	 264	(94.3)	 365	(45.3)	
ECOG	PS*	 	
0	 41	(17.6)	 76	(25.9)	 81	(28.9)	 198	(24.6)	
1	 162	(69.5)	 187	(63.8)	 167	(59.6)	 516	(64.0)	
2	 27	(11.6)	 28	(9.6)	 31	(11.1)	 86	(10.7)	
3-4	 3	(1.3)	 2	(0.7)	 0	(0.0)	 5	(0.6)	
Missing	 0	(0.0)	 0	(0.0)	 1	(0.4)	 1	(0.1)	
Total	radiation	dose	 	
54-63	Gy	 56	(24.0)	 51	(17.4)	 34	(12.1)	 141	(17.5)	
64-66	Gy	 162	(69.5)	 129	(44.0)	 7	(2.5)	 298	(37.0)	
68-70	Gy	 7	(3.0)	 112	(38.2)	 235	(83.9)	 354	(43.9)	
>70	Gy	 0	(0.0)	 1	(0.3)	 4	(1.4)	 5	(0.6)	
Missing	 8	(3.4)	 0	(0.0)	 0	(0.0)	 8	(1.0)	
*=Eastern	Cooperative	Oncology	Group	Performance	status 
	
Table	2b:	Tumor	information	of	locally	advanced	NSCLC	patients	
	 2002-2006	 2007-2011	 2012-2016	 Total	
	 No.	of	patients	(%)	
Histological	diagnosis	 	
Squamos	cell	
carcinoma	
82	(35.2)	 104	(35.5)	 110	(39.3)	 296	(36.7)	
Adenocarcinoma	 112	(48.1)	 136	(46.4)	 126	(45.0)	 374	(46.4)	
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NSCLC	NOS*	 0	(0.0)	 1	(0.3)	 0	(0.0)	 1	(0.1)	
Tumor	location,		
side	
	
Right	 140	(60.1)	 163	(55.6)	 162	(57.9)	 465	(57.7)	
Left	 90	(38.6)	 126	(43.0)	 117	(41.8)	 333	(41.3)	
Missing	 3	(1.3)	 4	(1.4)	 1	(0.4)	 (1.0)	
Tumor	location,	lobe	 	
Main	bronchus	 24	(10.3)	 11	(3.8)	 17	(6.1)	 52	(6.5)	
Upper	lobe	 129	(55.4)	 155	(52.9)	 148	(52.9)	 432	(53.6)	
Middle	lobe	 12	(5.2)	 14	(4.8)	 10	(3.6)	 36	(4.5)	
Lower	lobe	 59	(25.3)	 102	(34.8)	 95	(33.9)	 256	(31.8)	
Missing	 9	(3.9)	 11	(3.8)	 10	(3.6)	 30	(3.7)	
Cancer	stage	 	 	 	 	
IA-IIB	 49	(21.0)	 62	(21.2)	 48	(17.1)	 159	(19.7)	
IIIA	 53	(22.7)	 89	(30.4)	 123	(43.9)	 265	(32.9)	
IIIB	 113	(48.5)	 122	(41.6)	 90	(32.1)	 325	(40.3)	
IV	 18	(7.7)	 19	(6.5)	 15	(5.4)	 52	(6.5)	
Missing	 0	(0.0)	 1	(0.3)	 4	(1.4)	 5	(0.6)	
*=NSCLC	Not	otherwise	specified	
 
 
Table	2c:	p-values	and	Hazard	ratios	for	variables	in	the	locally	advanced	NSCLC	group	
Variable	 p-value	in	
univariate	
analysis	
HR	(95%	CI)	 p-value	in	multivariate	
analysis	
	
Treatment	interval	
2002-2006	
2007-2011	
2012-2016	
0.037		 	
Reference	
1.01	(0.80	-	1.27)	
0.95	(0.70	-	1.30)	
	
	
0.926	
0.761	
Gender	
Female	
Male	
<0.001	
	
	
Reference	
1.35	(1.13	–	1.61)	
	
	
<0.001	
Smoking	habits	
Smoker	
Ex-smoker	
Never-smoker	
0.045	
	
	
Reference	
0.95	(0.79	–	1.15)	
0.75	(0.53	–	1.05)	
	
	
0.617	
0.091	
Tumor	location,	lobe	
Main	bronchus	
Upper	lobe	
Middle	lobe	
Lower	lobe	
0.004	 	
Reference	
1.05	(0.73	–	1.49)	
0.69	(0.39	–	1.22)	
1.44	(1.00	–	2.08)	
	
	
0.796	
0.197	
0.0501	
Stage	of	cancer	
IA-IIB	
IIIA	
IIIB	
IV	
<0.001	
	
	
Reference	
1.24	(0.96	–	1.60)	
1.46	(1.14	–	1.87)	
2.01	(1.36	–	2.97)	
	
	
0.093	
0.003	
<0.001	
ECOG	Performance	status	
0	
1	
2	
3-4	
<0.001	
	
	
Reference	
1.36	(1.09	–	1.70)	
1.98	(1.45	–	2.70)	
3.05	(0.93	–	9.94)	
	
	
0.007	
<0.001	
0.065	
Age	at	start	of	treatment	
Continuous	variable	
0.91	 	
1.00	(0.99	–	1.01)	
	
0.558	
Total	radiation	dose	
54-63	Gy	
64-66	Gy	
68-70	Gy	
>70	Gy	
<0.001	
	
	
	
Reference	
1.01	(0.80	–	1.29)	
0.82	(0.62	–	1.07)	
3.11	(1.21	–	8.02)	
	
	
0.911	
0.147	
0.019	
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Figure	2.1,	Overall	survival	among	patients	with	locally	advanced	Non-Small	Cell	Lung	Carcinoma	depending	on	during	
which	time	interval	patients	received	their	treatment		
	
	
	
	
	
Figure	2.2,	Overall	survival	among	patients	with	locally	advanced	Non-Small	Cell	Lung	Carcinoma	depending	the	gender	of	
the	patients		
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Figure	2.3,	Overall	survival	among	patients	with	locally	advanced	Non-Small	Cell	Lung	Carcinoma	depending	on	the	ECOG	
performance	status	score	of	patients	
 
	
	
Figure	2.4,	Overall	survival	among	patients	with	locally	advanced	Non-Small	Cell	Lung	Carcinoma	depending	on	the	stage	of	
the	cancer	
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Curative chemoradiotherapy for SCLC 
Three-year survival in the SCLC chemoradiotherapy group was 28 %, 25 % and 20 % for 
2002-2006, 2007-2011 and 2012-2016 respectively. Estimates of five-year survival was 
calculated to 18 % for 2002-2006 and 17 % for 2007-2011. There were no significant 
differences in survival between time intervals (Figure 3y SCLC-5y SCLC). Median survival 
was estimated to 18.5, 16.7 and 16.1 months for each treatment period. Details on the SCLC 
population is shown in Table 3a-b. The results of the Cox proportional hazard model are 
showed in Table 3c. 
     In the analysis of potential factors for survival, a borderline significant gender difference 
in favor of female sex was observed, with a HR of 1.37 for three-year survival (95 % CI 1.00 
– 1.89, p=0.051). No significant gender difference was observed in five-year survival. A trend 
for inferior three- and five-year survival with regard to increased ECOG PS score was also 
observed, with significant differences between PS=0 vs. PS=1. 
     Age at the start of treatment was analyzed as a continuous variable. Age did not have an 
impact on five-year survival, but a significant result was noted in three-year survival 
(HR=1.02, 95 % CI 1.00 – 1.04, p=0.04). 
     There were no significant differences in survival with regard to time interval, laterality or 
lobar location of the tumor, stage of cancer or TNM-stage, smoking habits or radiation dose. 
However, a positive trend favoring 60 Gy over 45 was noted (see Fig. 3.5 in Appendix C).  
     Treatment interval, smoking habits, gender, ECOG PS, stage of cancer, lobar location of 
the tumor and radiation dose were considered important factors and were included in the 
model. TNM and side of the tumor were also analyzed but did not have an impact on survival 
and was not included in the model. 
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Table	3a:	Demographics	of	the	SCLC	group	
	 2002-2006	 2007-2011	 2012-2016	 Total	
Median	age	(range)	 65	(37-78)	 67	(44-85)	 67	(47-84)	 -	
	 No.	of	patients	(%)	
Patients	treated	with	
radiotherapy	for	SCLC	 100	 90	 79	 269	
Gender	 	
Female	 54	(54.0)	 48	(53.3)	 50	(63.3)	 152	(56.5)	
Male	 46	(46.0)	 42	(46.7)	 29	36.7)	 117	(43.5)	
Smoking	status	 	
Smokers	 66	(66.0)	 60	(66.7)	 62	(78.5)	 188	(69.9)	
Ex-smokers	 34	(34.0)	 27	(30.0)	 16	(20.3)	 77	(28.6)	
Non-smokers	 0	(0.0)	 3	(3.3)	 0	(0.0)	 3	(1.1)	
Missing	 0	(0.0)	 0	(0.0)	 1	(1.3)	 1	(0.4)	
	Diagnostic	PET-CT	 	
No	 100	(100.0)	 82	(91.1)	 49	(62.0)	 231	(85.9)	
Yes	 0	(0.0%)	 8	(8.9)	 30	(38.0)	 38	(14.1)	
ECOG	PS	 	
0	 18	(18.0)	 14	(15.6)	 18	(22.8)	 50	(18.6)	
1	 63	(63.0)	 53	(58.9)	 44	(55.7)	 160	(59.5)	
2	 15	(15.0)	 18	(20.0)	 13	(16.5)	 46	(17.1)	
3-4	 4	(4.0)	 5	(5.6)	 4	(5.1)	 13	(4.8)	
Total	radiation	dose	 	
45	Gy	 42	(42.0)	 46	(51.1)	 50	(63.3)	 138	(51.3)	
60	Gy	 57	(57.0)	 44	(48.9)	 28	(35.4)	 129	(48.0)	
Missing	 1	(1.0)	 0	(0.0)	 1	(1.3)	 2	(0.7)	
 
	
Table	3b:	Tumor	information	of	SCLC	patients	
	 2002-2006	 2007-2011	 2012-2016	 Total	
	 No.	of	patients	(%)	
Tumor	location,	side	 	
Right	 60	(60.0)	 51	(56.7)	 55	(69.6)	 166	(61.7)	
Left	 34	(34.0)	 37	(41.1)	 23	(29.1)	 94	(34.9)	
Missing	 6	(6.0)	 2	(2.2)	 1	(1.3)	 9	(3.3)	
Tumor	location,	lobe	 	
Main	bronchus	 9	(9.0)	 14	(15.6)	 12	(15.2)	 35	(13.0)	
Upper	lobe	 52	(52.0)	 43	(47.8)	 37	(46.8)	 132	(49.1)	
Middle	lobe	 4	(4.0)	 4	(4.4)	 4	(5.1)	 12	(4.5)	
Lower	lobe	 20	(20.0)	 16	(17.8)	 16	(20.3)	 52	(19.3)	
Missing	 15	(15.0)	 13	(14.4)	 10	(12.7)	 38	(14.1)	
Cancer	stage	 	 	 	 	
IA-IIB	 14	(14.0)	 8	(8.9)	 12	(15.2)	 34	(12.6)	
IIIA	 22	(22.0)	 17	(18.9)	 17	(21.5)	 56	(20.8)	
IIIB	 56	(56.0)	 56	(62.2)	 43	(54.4)	 155	(57.6)	
IV	 8	(8.0)	 9	(10.0)	 6	(7.6)	 23	(8.6)	
Missing	 0	(0.0)	 0	(0.0)	 1	(1.3)	 1	(0.4)	
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Table	3c:	p-values	and	Hazard	ratios	for	variables	in	the	SCLC	group	
Variable	 p-value	in	
univariate	
analysis	
HR	(95%	CI)	 p-value	in	multivariate	
analysis	
	
Treatment	interval	
2002-2006	
2007-2011	
2012-2016	
0.495	 	
Reference	
0.97	(0.67	–	1.40)	
1.25	(0.85	–	1.84)	
	
	
0.852	
0.255	
Gender	
Female	
Male	
<0.001	 	
Reference	
1.37	(1.00	–	1.89)	
	
	
0.051	
Smoking	habits	
Smoker	
Ex-smoker	
Never-smoker	
0.353	 	
Reference	
0.96	(0.68	–	1.37)	
0.00	(0.00	–	Inf)	
	
	
0.840	
0.993	
Tumor	location,	lobe	
Main	bronchus	
Upper	lobe	
Middle	lobe	
Lower	lobe	
0.920	 	
Reference	
0.81	(0.51	–	1.28)	
0.81	(0.38	–	1.71)	
0.81	(0.47	–	1.38)	
	
	
0.374	
0.573	
0.433	
Stage	of	cancer	
IA-IIB	
IIIA	
IIIB	
IV	
0.022	 	
Reference	
0.79		(0.46	–	1.36)	
0.86	(0.53	–	1.39)	
1.34	(0.69	–	2.61)	
	
	
0.398	
0.541	
0.391	
ECOG	Performance	status	
0	
1	
2	
3-4	
0.058	 	
Reference	
1.91	(1.18	–	3.09)	
1.76	(0.98	–	3.16)	
1.98	(0.77	–	5.10)	
	
	
0.008	
0.060	
0.156	
Age	at	start	of	treatment	
Continuous	variable	
0.008	 	
1.02	(1.00	–	1.04)	
	
0.037	
Total	radiation	dose	
45	Gy	
60	Gy	
0.174	
	
	
Reference	
0.95	(0.67	–	1.34)	
	
	
0.759	
	
	
	
	
	
	
	
Figure	3.1,	Overall	survival	among	patients	with	Small	Cell	Lung	Carcinoma	depending	on	during	which	time	interval	
patients	received	their	therapy	
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Figure	3.2,	Overall	survival	among	patients	with	Small	Cell	Lung	Carcinoma	depending	on	the	gender	of	the	patients	
 
 
 
	
	
Figure	3.3	Overall	survival	among	patients	with	Small	Cell	Lung	Carcinoma	depending	the	stage	of	the	cancer	
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Discussion  
This is one of the first studies that provides real life data on overall survival for lung cancer 
patients treated with modern radiotherapy with curative intent in Sweden. During the time 
period of the study (2002-2016) the patient number has increased with regards to SBRT, 
initially increased and then been rather stable for NSCLC treated with chemoradiotherapy, 
and slightly decreased with regard to SCLC. More than 3 times as many patients received 
SBRT in 2012-2016 compared to 2002-2006 (see Table 1a). There has been a gradual rise in 
popularity in SBRT lung cancer treatment after it was first described in 1995 by Blomgren et 
al. (47). One explanation for this is that more patients with comorbidities previously 
considered too severe to qualify for either surgery or conventional radiotherapy have in more 
recent years been referred to SBRT, and another explanation could be a more frequent use of 
CT of the thorax and implementation of PET/CT in diagnostic and staging procedures of lung 
cancer, that has led to the diagnosis of more T1 and T2 tumors than before – tumors that are 
potentially eligible for SBRT. The decreased number treated for SCLC probably reflects the 
overall declining incidence of SCLC (see Table 3a).  
     Regarding the overall survival rate for SBRT, the real-life data (47-55 % in three-year 
survival and 30 % for five-year survival) actually comes close to what is reported in 
prospective clinical trials. A few prospective trials including one randomized clinical trial on 
similar patient populations in Sweden treated with SBRT has been published previously. In 
the randomized SPACE-study from 2016 performed by Nyman et al., a 3-year overall 
survival of 54 % for SBRT patients was reported (30), while two prospective phase II trials 
estimated a three-year overall survival of 60 % and a five-year overall survival of 30 % 
respectively (33, 48). The same finding was observed for patients with locally advanced 
NSCLC. Hallqvist et al. and Nyman et al. have performed two clinical trials (published in 
2011 and 2009 respectively) on locally advanced NSCLC patient populations in Sweden and 
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found three-year OS rates of 29 % and 31 % respectively (49, 50), compared to 24-35 % in 
this study. Generally, it is important not to be too hasty and presume that study results from 
clinical trials apply on everyday patients, since they often overestimate the effect in clinical 
reality due to the selection of the included patients. However, this study suggests that NSCLC 
patients in VGR actually have comparable survival rates to what is reported in these clinical 
trials, and the trend over time for patients treated with chemoradiotherapy is at least in the 
right direction.   
     With regard to the SCLC group, a more discouraging trend was observed in survival by 
treatment interval, albeit not statistically significant. Data suggests that the survival rate for 
SCLC patients may have declined in recent years (see Fig. 3.1), despite the presumed 
improvements in staging and radiation techniques. Furthermore, OS appears to be lower than 
data from contemporary prospective trials. A Norwegian trial published in 2016 reported a 
five-year survival of 25 % for SCLC patients treated with chemoradiotherapy, and patients 
treated with 45 Gy in 30 twice daily fractions had a median OS of 25.1 months (51, 52). 
Moreover, a 22 % five-year survival for limited disease SCLC was reported by Shild et al. in 
a randomized clinical phase II trial in 2004, while Chen et al. reported a median OS of 24 
months in their clinical trial from 2005 (53, 54). Survival rates in VGR are markedly lower 
according to our study - five-year survival is only 16.7-18.2 % and the median OS 16.1-18.5 
months. The inferior results could be due to selection bias in the prospective trials, but the 
downward trend need further scrutinizing. Does dose matter (see below)? Or could choice of 
concurrent chemotherapy impact on the results? All SCLC patients in the previously 
mentioned studies with superior outcomes were treated with cisplatin-based chemotherapy 
regimens (51-54). However, carboplatin is widely used instead of cisplatin as it is much easier 
to administrate, and it is nowadays used in the standard therapy in VGR (55). Some efforts 
have been made to evaluate if there is a difference in efficacy between carboplatin and 
	 38	
cisplatin but no significant difference has been found in SCLC. There are, however, only very 
few randomized clinical trials comparing the two and they are all conducted on small 
populations in which a majority of patients had stage IV disease (56-59). The results from 
these studies are therefore not necessarily applicable to SCLC patients with limited disease 
receiving radiotherapy, and one could speculate whether cisplatin is in fact more effective 
than carboplatin in treating stage I-III SCLC. Most international guidelines argue for the use 
of cisplatin in chemoradiotherapy of SCLC with curative intent, referring to the lack of 
comparative phase III data on carboplatin vs cisplatin and the extensive amount of data on the 
effectiveness of cisplatin as e.g. stated by Woolf et al. and Stinchcombe et al. (60, 61). Taking 
all this into account, it is possible that the gradual transition to more carboplatin-based 
chemoradiotherapy regimens in VGR could have contributed to the impaired outcome of 
stage I-III SCLC patients in recent years. 
     One of the objectives of this report was to evaluate the impact of total radiation dose on 
survival and to compare the outcome from currently recommended doses to previous 
recommendations. In the SBRT group, the 45 Gy is the current standard SBRT dose and the 
other regimens of 40 Gy (4 x 10 Gy) and 56 Gy (7 x 8 Gy) are two variants of risk-adapted 
SBRT for tumors in high-risk locations that results in a lower biological effective dose (BED) 
than 45 Gy in 3 fractions (16, 55). Therefore, one could hypothesize those regimens to have 
inferior treatment results compared to the more potent dose 15 x 3 Gy. In this data set, 
however, the 45 Gy group performed only numerically better – there were no significant 
difference in survival between regimens. It could be that the lower doses are enough – 7 Gy x 
8 is still a potentially curative dose, but it could also be due to small group sizes: 26 patients 
received 40 Gy while only 12 received 56 Gy, compared to 306 patients with 45 Gy. No 
significant differences in OS with regard to radiation dose could be observed for locally 
advanced NSCLC patients treated with chemoradiotherapy either. The different dose levels in 
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this group (54-63 Gy, 64-66 Gy, 68-70 Gy) are biologically rather similar, so it would 
probably take a very large patient population to detect any possible difference in treatment 
outcome. However, a reassuring trend was observed favoring the currently recommended 68-
70 Gy compared to the other doses (see Figure 2.6 in Appendix C), indicating that the current 
clinical practice for treatment of locally advanced NSCLC probably is a step in the right 
direction. In the SCLC group, hyperfractionated radiotherapy of either 45 Gy or 60 Gy were 
used (1.5 Gy twice daily for 30-40 days). 45 Gy in this setting is biologically a lower dose 
than 60 Gy, and the recommendation in VGR is to use 45 Gy in patients with poor lung 
function and/or other severe comorbidities (55). Despite this potentially negative selection, 
only a statistically not significant tendency for improved survival with 60 Gy was observed. 
Maybe small group sizes could explain why the more potent dose did not result in 
significantly superior survival, but when taking the radiosensitivity of SCLC tumors into 
account it is possible that 45 Gy is a high enough radiation dose. On the other hand, the use of 
the 60 Gy schedule has decreased compared to the 45 Gy schedule in recent years, coinciding 
in time with the period of decreased survival. A Norwegian trial comparing 45 Gy vs 60 Gy in 
SCLC (in which Sahlgrenska University Hospital participated) has just finished, and it will be 
interesting to see how our results compare to theirs when they are published. 
     PET/CT significantly improved survival in the univariate analysis with regard to patients 
treated with SBRT, but not in the multivariate analysis. Patients that are suited for SBRT 
generally have other severe comorbidities that make them unfit for surgery, and most deaths 
in the SBRT group are presumably from other causes than lung cancer, as this has been the 
case in similar studies on SBRT populations (33). Impact on lung cancer survival from 
technical advances like PET/CT could therefore be difficult to illustrate in this kind of 
population with relatively frail patients. It would therefore be interesting to investigate the 
impact of PET/CT on early stage NSCLC patients eligible 
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neutralize this particular problem with SBRT cohorts. Somewhat surprisingly, no significant 
effect was observed due to PET/CT in NSCLC patients treated with chemoradiotherapy 
either. However, since data on use of PET/CT was only available from 2007, a separate 
analysis taking only the two latter treatment periods into account were performed to more 
accurately estimate the impact PET/CT had on survival. A negative aspect of analyzing 
PET/CT in this way is that it resulted in a much smaller amount of data with too many 
different variables in the analysis, thus making the results unreliable. 
     There was a gender difference in survival in favor of women in the SBRT group as well as 
for the patients with locally advanced NSCLC. A borderline significant difference in 3-year 
survival for the SCLC chemoradiotherapy group (HR=1.4, 95 % CI 1.00 – 1.89, p=0.051) was 
also observed. These results are not surprising since there is consistent evidence from 
previous research that female sex predicts better survival in lung cancer, especially in NSCLC 
(62, 63). Concerning gender, it is also noteworthy that the growing proportion of women in 
the SCLC population over time should be associated to an increase in survival rather than the 
decrease seen in this study. 
     Age of the patient was not shown to have an impact on survival in either of the SBRT or 
locally advanced NSCLC groups. This finding is in line with several previously published 
studies that has concluded that advanced age alone does not cause a poorer survival (64, 65). 
The results emphasize that assessment before therapy should be focused on comorbidities and 
performance status of the patient rather than age as a growing risk due to increased ECOG PS 
score was observed throughout all treatment groups. Patients should therefore not be denied 
effective curative radiotherapy solely because of old age, and our results highlights the 
importance of consistent performance status assessments of lung cancer patients before a 
treatment strategy is decided upon. Regarding the SCLC group, age seemed to significantly 
affect survival. The increased risk regarding old age was estimated to a HR=1.02, which 
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translates to a substantial annual increase in risk for a patient. This result is somewhat 
surprising, as the impact of old age is usually diminished when considered together with 
performance status (30, 49). However, age was analyzed as a continuous variable and not by 
age-groups in this study, which may have affected the result. This divergent result needs to be 
evaluated further, and our intention is to re-analyze age divided into age-groups and then see 
if a significant difference regarding age still remains. 
     The prognostic value of the site of the tumor was also assessed. The results suggest that 
survival in NSCLC is affected by the lobar location – the lower lobe was associated with an 
inferior survival in both the locally advanced NSCLC group and the SBRT group. Lobar 
location of lung cancer and its impact on survival is a controversial subject. In the field of 
thoracic surgery, lung tumors located in the left lower lobe are traditionally considered to 
predict an increased mortality (66-68), a notion that is in line with our findings. As the 
amount of literature describing survival based upon lobar location is scarce in the context of 
radiotherapy, further investigation of this concept is of interest.  
     As expected, stage significantly impacts on survival, and in NSCLC patients treated with 
chemoradiotherapy, it was also evident in stage in stage IIIA to IIIB. A trend was observed 
between T1 and T2 tumors treated with SBRT but for patients with SCLC the outcome for 
patients without distant spread was similar. 
 
Methodological considerations 
This study is one of the first retrospective studies that provides real-life data on lung cancer 
patients in VGR, which is an advantage in itself. A major strength is that it is a 
comprehensive population-based study including all lung cancer patients in VGR that have 
received radiotherapy between 2002-2016, rather than a selected cohort, thus minimizing the 
risk for selection bias.  
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     There are, however, several shortcomings in this study. One of them is that we did not 
include patient data on weight loss (since no such data was recorded in the quality registers 
we used), which is a very important independent prognostic factor (69-71). Major weight loss 
in lung cancer patients before the start of treatment results in substantially worse outcome. It 
is possible that there were imbalances in distribution of weight loss between the patient 
cohorts, consequently affecting the results unbeknownst to us. 
     One of the problems with performing a retrospective cohort study is that one has to rely on 
others for correct recordkeeping. This should not have been a major problem in this study, 
since we mainly used solid data recorded in quality registers (assuming data have been 
accurately documented in the quality registers). However, there were 159 patients in our 
material that were missing in the quality registers, and for whom we had to go through 
medical journals and interpret recorded information on variables such as performance status, 
smoking habits and TNM-stage. As this information was not always straightforwardly 
documented in the medical records, there is a possible risk that we have misinterpreted some 
of the data for these patients. 
     Chemoradiotherapy regimens in lung cancer usually starts with a cycle of chemotherapy 
before the radiotherapy is started. On rare occasions, cancer patients suffer fatal infections 
during chemotherapy before their radiotherapy is finished or even started. A limitation with 
this study is that no such cases are taken into account, since only patients that completed their 
entire chemoradiotherapy schedule were included. 
     Regarding the PET/CT analyses, we chose to exclude all patients treated in the earliest 
time interval (2002-2006), as PET/CT was implemented in clinical practice in 2010. PET/CT 
was then analyzed together with the other variables in separate multivariate models. However, 
this resulted in a much smaller amount of data and there are uncertainties in the multivariate 
models regarding the PET/CT analyses, especially since there are so many variables included 
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in the model. This is an important limitation of this study, since one of our main objectives 
was to evaluate the impact that use of PET/CT for staging and diagnostics has had on the 
outcome for lung cancer patients. 
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Conclusion 
This study suggests that overall survival for NSCLC patients in VGR treated with SBRT or 
chemoradiotherapy is equal to what has been reported in clinical trials previously. No 
significant differences in survival over time was observed for either of the three groups but a 
trend for improved survival was seen in the locally advanced NSCLC group, albeit not 
statistically significant. In contrast, SCLC patients in VGR seem to have slightly inferior 
survival rates compared to corresponding studies, and there is also a trend for declining 
survival in more recent years, which warrants further investigation.  
     Female sex had a protective impact on survival for both NSCLC and SCLC patients. Our 
results also indicate that it is more important to consider a poor performance status rather than 
old age before deciding on potentially curative treatments for NSCLC patients.  
     Tumors located in the lower lobe were associated with an inferior survival in NSCLC 
patients. The reason for this association is unknown and needs to be further studied.  
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Populärvetenskaplig sammanfattning 
Utvärdering av behandlingsresultat för lungcancerpatienter i Västra Götalandsregionen 
som fått strålbehandling i botande syfte 
Lungcancer är en av världens vanligaste cancersjukdomar och samtidigt den cancer som 
dödar flest människor årligen. Huvudsakligen delas lungcancer in i två undergrupper med 
olika karakteristika och som kräver olika behandlingsstrategier: Småcellig lungcancer (SCLC) 
och icke-småcellig lungcancer (NSCLC). Kirurgi, strålbehandling och cellgifter är de främsta 
potentiellt botande behandlingsmetoderna mot lungcancer. Strålbehandling, även kallat 
radioterapi eller radiokemoterapi när det kombineras med cellgifter, ges årligen till över 
hundra lungcancerpatienter i Västra Götalandsregionen (VGR), men hur 
behandlingsresultaten ser ut i praktiken är ännu inte utvärderat. Det här projektets syfte var 
därför att utvärdera överlevnaden bland lungcancerpatienter som har strålbehandlats i VGR 
mellan år 2002 och 2016. I studien undersöktes ett antal olika faktorer som förmodas kunna 
ha en inverkan på överlevnaden, t ex kön, ålder, hälsotillstånd, rökning, total stråldos, 
tidsperiod för behandling eller användning av nya tekniker såsom PET/CT.   
     För att besvara vår frågeställning utförde vi en retrospektiv studie, dvs en studie där vi 
tittade tillbaka på hur det gått för lungcancerpatienter som behandlats med strålterapi i VGR 
mellan år 2002 och 2016. Totalt räknades 1421 lungcancerpatienter med i studien och 
information om dem, deras lungcancer och strålbehandlingen hämtades från patientjournaler 
och olika cancerregister. Patienter delades in i tre olika huvudgrupper: strålbehandling för 
lokalt begränsad NSCLC, radiokemoterapi för lokalt spridd NSCLC och radiokemoterapi för 
SCLC. Överlevnaden samt hur denna påverkades av de olika faktorerna analyserades sedan 
inom varje grupp. 
     I våra statistiska analyser kunde vi till att börja med se att överlevnaden i princip hållit sig 
oförändrad över tid för de olika patientgrupperna trots de tekniska framsteg som gjorts inom 
	 47	
strålbehandling och diagnostik på senare år. I gruppen med lokalt avancerad NSCLC kunde 
möjligen en tendens till förbättring ses för senare år, men detta fynd var osäkert. Vi kunde 
också se att överlevnaden för NSCLC-patienter i vår studie var jämförbar med överlevnaden 
som rapporterats i tidigare liknande studier. Patienter med SCLC uppvisade dock en klart 
sämre överlevnad än vad som tidigare rapporterats, dessutom med en tendens till en allt sämre 
överlevnad på senare år. Orsaken till varför det ser ut så här är okänd och behöver utredas 
vidare.  
     När det gäller de olika faktorerna med potentiell påverkan på överlevnaden så kunde vi se 
att manligt kön och ett dåligt hälsotillstånd vid behandlingsstarten medförde en sämre 
överlevnad vid strålbehandling för lungcancer. För patienter med NSCLC spelade det inte 
någon roll hur gammal patienten var vid behandlingsstarten – gamla patienter gynnades lika 
mycket av botande strålterapi som unga. För patienter med SCLC verkade det däremot som 
att en hög ålder medförde en sämre överlevnad, vilket talar för att botande strålterapi kan vara 
för farligt för de äldsta patienterna med SCLC oavsett hur bra deras hälsotillstånd är. Våra 
resultat visar också att NSCLC-tumörer som sitter i lungans underlob är farligare än tumörer 
belägna på andra ställen i lungan. Orsaken till detta samband är inte heller känt utan behöver 
utredas vidare.  
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Appendices 
Appendix A: Graphs and tables of the supplementary multivariate PET/CT analysis 
for the SBRT group 
 
	
	
	
	
	
	
	
	
	
	
	
Figure	1.7,	Three-year	survival	for	SBRT	patients	by	total	SBRT	dose	
 
Figure	1.6,	Three-year	survival	for	SBRT	patients	by	smoking	habits	
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Table	1d:	p-values	and	Hazard	ratio	of	the	supplementary	PET/CT	analysis	for	the	SBRT	group	
Variable	 p-value	in	
univariate	
analysis	
HR	(95%	CI)	 p-value	in	
multivariate	
analysis	
	
Treatment	interval	
2007-2011	
2012-2016	
0.23	
	
	
Ref.	
0.87	(0.60	–	1.26)	
	
	
0.46	
Gender	
Female	
Male	
0.003	
	
	
Ref.	
1.59	(1.11	–	2.27)	
	
	
0.01	
Smoking	habits	
Smoker	
Ex-smoker	
Never-smoker	
0.71	 	
Ref.	
0.82	(0.57	–	1.18)	
0.62	(0.32	–	1.22)	
	
	
0.28	
0.17	
Tumor	location,	lobe	
Upper	lobe	
Middle	lobe	
Lower	lobe	
0.02	 	
Ref.	
0.95	(0.38	–	2.40)	
1.52	(1.07	–	2.16)	
	
	
0.92	
0.02	
Use	of	PET/CT	
No	
Yes	
0.03	 	
Ref.	
0.78	(0.48	–	1.27)	
	
	
0.32	
ECOG	Performance	status	
0	
1	
2	
3-4	
0.003		 	
Ref.	
1.51	(0.81	–	2.81)	
1.87	(0.98	–	3.58)	
5.22	(2.16	–	12.58)	
	
	
0.20	
0.06	
<0.001	
T-stage	
T1	
T2	
0.005	
(<0.01?)	
	
Ref.	
1.46	(1.01	–	2.10)	
	
	
0.04	
Age	at	start	of	treatment	
Continuous	variable	
0.20	 	
1.02	(0.99	–	1.04)	
	
0.20	
Total	radiation	dose	
40	Gy	
45	Gy	
56	Gy	
0.23	 	
Ref.	
0.71	(0.41	–	1.22)	
0.91	(0.34	–	2.45)	
	
	
0.22	
0.85	
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Appendix B: Graphs and tables of the supplementary multivariate PET/CT analysis 
for the locally advanced NSCLC group 
Table	2d:	p-values	and	Hazard	ratios	of	the	supplementary	PET/CT	analysis	for	the	locally	advanced	NSCLC	group	
Variable	 p-value	in	
univariate	
analysis	
HR	(95%	CI)	 p-value	in	
multivariate	
analysis	
	
Treatment	interval	
2007-2011	
2012-2016	
0.15	 	
Ref.	
0.98	(0.73	–	1.32)	
	
	
0.91	
Gender	
Female	
Male	
0.002	 	
Ref.	
1.44	(1.16	–	1.78)	
	
	
<0.001	
Smoking	habits	
Smoker	
Ex-smoker	
Never-smoker	
0.09	 	
Ref.	
0.96	(0.77	–	1.20)	
0.78	(0.51	–	1.18)	
	
	
0.74	
0.24	
Tumor	location,	lobe	
Main	bronchus	
Upper	lobe	
Middle	lobe	
Lower	lobe	
0.002	 	
Ref.	
1.13	(0.70	–	1.84)	
0.43	(0.19	–	0.99)	
1.49	(0.91	–	2.44)	
	
	
0.61	
0.048	
0.11	
Use	of	PET/CT	
No	
Yes	
0.07	 	
Ref.	
0.91	(0.69	–	1.21)	
	
	
0.53	
Stage	of	cancer	
IA-IIB	
IIIA	
IIIB	
IV	
0.005	 	
Ref.	
1.32	(0.97	–	1.79)	
1.52	(1.12	–	2.08)	
2.32	(1.43	–	3.76)	
	
	
0.08	
0.01	
<0001	
ECOG	Performance	status	
0	
1	
2	
3-4	
<0.001	 	
Ref.	
1.50	(1.15	–	1.96)	
1.86	(1.27	–	2.74)	
1.29	(0.16	–	10.05)	
	
	
0.003	
0.001	
0.81	
Age	at	start	of	treatment	
Continuous	variable	
0.053	 	
1.01	(1.00	–	1.02)	
	
0.08	
Total	radiation	dose	
54-63	Gy	
64-66	Gy	
68-70	Gy	
>70	Gy	
0.002	 	
Ref.	
0.99	(0.71	–	1.40)	
0.82	(0.60	–	1.11)	
3.35	(1.28	–	8.77)	
	
	
0.97	
0.20	
0.01	
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Figure	2.5,	Five-year	survival	by	time	interval	for	locally	advanced	NSCLC	patients		
 
 
	
Figure	2.6,	Three-year	survival	by	total	radiotherapy	dose	for	locally	advanced	NSCLC	patients	
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Figure	2.7,	Three-year	survival	by	smoking	habits	for	locally	advanced	NSCLC	patients	
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Appendix C: Graphs and tables of the supplementary multivariate PET/CT analysis 
for the SCLC group 
Table	3d:	p-values	and	Hazard	ratios	of	the	supplementary	PET/CT	analysis	for	the	SCLC	group	
Variable	 p-value	in	
univariate	
analysis	
HR	(95%	CI)	 p-value	in	
multivariate	analysis	
	
Treatment	interval	
2007-2011	
2012-2016	
0.42	 	
Ref.	
1.28	(0.85	–	1.94)	
	
	
0.24	
Gender	
Female	
Male	
0.08	 	
Ref.	
1.28	(0.85	–	1.91)	
	
	
0.23	
Smoking	habits	
Smoker	
Ex-smoker	
Never-smoker	
0.35	 	
Ref.	
0.77	(0.49	–	1.23)	
0.00	(0.00	–	inf.)	
	
	
0.28	
0.99	
Tumor	location,	lobe	
Main	bronchus	
Upper	lobe	
Middle	lobe	
Lower	lobe	
0.95	 	
Ref.	
0.88	(0.50	–	1.55)	
0.78	(0.29	–	2.08)	
0.92	(0.47	–	1.79)	
	
	
0.66	
0.62	
0.80	
Use	of	PET/CT	
No	
Yes	
0.71	 	
Ref.	
0.83	(0.49	–	1.40)	
	
	
0.48	
Stage	of	cancer	
IA-IIB	
IIIA	
IIIB	
IV	
0.054	 	
Ref.	
0.49	(0.24	–	0.99)	
0.53	(0.28	–	1.00)	
0.92	(0.38	–	2.21)	
	
	
0.046	
0.051	
0.85	
ECOG	Performance	status	
0	
1	
2	
3-4	
0.48	 	
Ref.	
1.68	(0.94	–	2.98)	
1.53	(0.75	–	3.13)	
1.43	(0.43	–	4.68)	
	
	
0.08	
0.24	
0.56	
Age	at	start	of	treatment	
Continuous	variable	
0.003	 	
1.04	(1.01	–	1.06	
	
0.003	
Total	radiation	dose	
45	Gy	
60	Gy	
0.20	 	
Ref.	
0.91	(0.58	–	1.43)	
	
	
0.68	
 
	
	
Figure	3.4,	Five-year	survival	by	time	interval	for	SCLC	patients	
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Figure	3.5,	Three-year	survival	by	total	radiation	dose	for	SCLC	patients		
 
	
Figure	3.6,	Three-year	survival	by	ECOG	performance	status	for	SCLC	patients	
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Figure	3.7,	Three-year	survival	by	smoking	habits	for	SCLC	patients	
 
	
 
	
Figure	3.8,	Three-year	survival	by	lobar	location	for	SCLC	patients	
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